白细胞介素-12和Flt3配体对表皮和真皮树突状细胞的差异调节

Differential regulation of epidermal and dermal dendritic cells by IL-12 and Flt3 ligand.

作者信息

Esche C, Subbotin V M, Hunter O, Peron J M, Maliszewski C, Lotze M T, Shurin M R

机构信息

University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA.

出版信息

J Invest Dermatol. 1999 Dec;113(6):1028-32. doi: 10.1046/j.1523-1747.1999.00779.x.

DOI:10.1046/j.1523-1747.1999.00779.x

PMID:10594747

Abstract

An abrogation of the decline in epidermal Langerhans cell numbers above melanoma might significantly improve the efficacy of immunotherapy for melanoma treatment. Systemic Flt3 ligand (FL) administration in mice induced a significant increase in mature dendritic cells (DC) within the skin, preferentially in the dermis, whereas IL-12 promoted a significant increase of immature DC preferentially in the epidermis. Both effects were abrogated in IL-12 knockout mice. Thus, IL-12 could promote FL-induced accumulation of skin DC. The involvement of FL and IL-12 in the regulation of DC accumulation within the skin may contribute, at least in part, to the stimulation of antimelanoma immunity by FL- and IL-12-based immunotherapies. Moreover, FL and IL-12 could be used for selective in vivo generation of DC in either epidermis or dermis for experimental and clinical purposes.

摘要

消除黑色素瘤上方表皮朗格汉斯细胞数量的减少可能会显著提高黑色素瘤免疫治疗的疗效。在小鼠中全身给予Flt3配体（FL）可诱导皮肤内成熟树突状细胞（DC）显著增加，优先在真皮层，而白细胞介素-12（IL-12）则优先促进表皮内未成熟DC显著增加。在IL-12基因敲除小鼠中，这两种效应均被消除。因此，IL-12可促进FL诱导的皮肤DC积累。FL和IL-12参与皮肤内DC积累的调节可能至少部分有助于基于FL和IL-12的免疫疗法刺激抗黑色素瘤免疫。此外，FL和IL-12可用于在表皮或真皮中选择性地在体内生成DC，用于实验和临床目的。